title: Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer.
abstract: BACKGROUND
  We performed short-term neoadjuvant chemotherapy (s-NAC) to examine whether anticancer drugs can change the proliferative ability of cancer cells in gastric cancer patients.
  
  
  METHODS
  Chemotherapy was performed for 72 h before gastrectomy in 63 gastric cancer patients. Patients were classed into four groups: Group F, 16 cases who received a single administration of 5-fluorouracil (5-FU); Group C, 15 cases who received a single administration of cis-diamminedichloroplatinum (CDDP; cisplatin); Group FC, 16 cases who received both 5-FU+CDDP; and a Control group, 16 cases who did not receive chemotherapy. We reviewed neoadjuvant biopsy tissue and gastric cancer tissue delivered by operation in these cases. The TUNEL method and immunohistochemistry with an anti-MIB-1 antibody were used to evaluate cellular apoptosis and proliferative ability, respectively. The apoptotic index (AI) and an MIB-1 index (MI) were also calculated.
  
  
  RESULTS
  There were no differences in AI or MI in biopsy tissue between the groups. The AI of gastric cancer tissue in Group FC was significantly higher than in the other groups (P < 0.01). The MI of Group FC was significantly lower than in the other groups (P < 0.05). In addition, after s-NAC operation there was a significant inhibition of proliferative potency and an induction of apoptosis in Group FC.
  
  
  CONCLUSIONS
  Combination of CDDP and 5-FU reduced proliferative potency and increased cellular apoptosis in gastric cancer cells.
authors.affiliation: Department of Surgery, Kinki University Faculty of Medicine, 377-2 Ohnohigashi, Osaka-Sayama, Osaka 589-8511, Japan. imano@med.kindai.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Imano
authors.forename: T
authors.initials: T
authors.lastname: Itoh
authors.forename: T
authors.initials: T
authors.lastname: Satou
authors.forename: Y
authors.initials: Y
authors.lastname: Sogo
authors.forename: H
authors.initials: H
authors.lastname: Hirai
authors.forename: H
authors.initials: H
authors.lastname: Kato
authors.forename: A
authors.initials: A
authors.lastname: Yasuda
authors.forename: Y F
authors.initials: YF
authors.lastname: Peng
authors.forename: M
authors.initials: M
authors.lastname: Shinkai
authors.forename: T
authors.initials: T
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Imamoto
authors.forename: K
authors.initials: K
authors.lastname: Okuno
authors.forename: H
authors.initials: H
authors.lastname: Shiozaki
authors.forename: H
authors.initials: H
authors.lastname: Ohyanagi
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001707:Biopsy, Needle; D016009:Chi-Square Distribution; D002945:Cisplatin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D005743:Gastrectomy / Q000379:methods; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D011446:Prospective Studies; D012016:Reference Values; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil